{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:12:40Z","timestamp":1790662360351,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005111","name":"Rigshospitalet","doi-asserted-by":"publisher","award":["Postdoctoral grant"],"award-info":[{"award-number":["Postdoctoral grant"]}],"id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Men with pathogenic\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      variants are at higher risk of prostate cancer We included men with likely pathogenic\/pathogenic (LP\/P) variants in\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      in a prostate-specific antigen (PSA) screening program after cascade germline testing since 2014. PSA was tested yearly and an age-specific low PSA threshold for biopsy was used, to determine if a low PSA threshold for biopsy is justified for men with pathogenic\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      variants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From 2014 to 2023 a total of 340 men were included in the program. We report demographics, clinical characteristics, and treatment outcomes at 7 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cumulative incidence of a primary biopsy was 37% (95CI: 31\u201243) after 7 years. Incidence of prostate cancer diagnosis was 11% (95CI: 7.1\u201215). Men referred were 7.8 (95CI: 5.3\u201211,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) times more likely to be diagnosed with prostate cancer than the general Danish male population. The cumulative incidence of biochemical failure (PSA\u2009&gt;\u2009=\u20090.2\u2009ng\/ml) 4 years after RP was 22% (95CI: 2.3\u201241). The main limitation is that not all men underwent a pre-biopsy MRI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      We found a high incidence of prostate cancer in men with LP\/P\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      variants, but this may be explained by the low PSA threshold for scheduling biopsies. More studies are needed to compare this patient population to men with other germline features. The high risk of recurrence after curative therapy is worrisome and requires further evaluation as to whether this is a biological phenomenon.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-025-00938-z","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T07:41:40Z","timestamp":1737445300000},"page":"894-901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1\/2 variants"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7293-9506","authenticated-orcid":false,"given":"Hein V.","family":"Stroomberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Brasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna A.","family":"Blak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Byrjalsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas van Overeem","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0019-5333","authenticated-orcid":false,"given":"Andreas","family":"R\u00f8der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"938_CR1","doi-asserted-by":"publisher","unstructured":"Tung NM, Garber JE. BRCA1\/2 testing: therapeutic implications for breast cancer management. Br J Cancer. 2018;119. https:\/\/doi.org\/10.1038\/s41416-018-0127-5.","DOI":"10.1038\/s41416-018-0127-5"},{"key":"938_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2021;19:77\u2013102.","journal-title":"J Natl Compr Cancer Netw"},{"key":"938_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.6004\/jnccn.2019.5011","volume":"17","author":"JL Mohler","year":"2019","unstructured":"Mohler JL, Antonarakis ES. NCCN guidelines updates: management of prostate cancer. J Natl Compr Cancer Netw. 2019;17:583\u20136. https:\/\/doi.org\/10.6004\/jnccn.2019.5011.","journal-title":"J Natl Compr Cancer Netw"},{"key":"938_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","volume":"15","author":"MF Berger","year":"2018","unstructured":"Berger MF, Mardis ER. The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol. 2018;15:353\u201365. https:\/\/doi.org\/10.1038\/s41571-018-0002-6.","journal-title":"Nat Rev Clin Oncol"},{"key":"938_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/gim.2017.118","volume":"20","author":"Z Chen","year":"2018","unstructured":"Chen Z, Kolor K, Grosse SD, Rodriguez JL, Lynch JA, Green RF, et al. Trends in utilization and costs of BRCA testing among women aged 18\u201364 years in the United States, 2003-2014. Genet Med. 2018;20:428\u201334. https:\/\/doi.org\/10.1038\/gim.2017.118.","journal-title":"Genet Med"},{"key":"938_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.2023.9526","volume":"330","author":"AW Kurian","year":"2023","unstructured":"Kurian AW, Abrahamse P, Furgal A, Ward KC, Hamilton AS, Hodan R, et al. Germline genetic testing after cancer diagnosis. JAMA. 2023;330:43 https:\/\/doi.org\/10.1001\/jama.2023.9526.","journal-title":"JAMA"},{"key":"938_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejca.2020.12.023","volume":"146","author":"P Pujol","year":"2021","unstructured":"Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, et al. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur J Cancer. 2021;146:30\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.023.","journal-title":"Eur J Cancer"},{"key":"938_CR8","first-page":"1122","volume":"19","author":"JM Weiss","year":"2021","unstructured":"Weiss JM, Gupta S, Burke CA, Axell L, Chen L-M, Chung DC, et al. NCCN Guidelines\u00ae Insights: Genetic\/Familial High-Risk Assessment: Colorectal, Version 1.2021. J Natl Compr Cancer Netw. 2021;19:1122\u201332.","journal-title":"J Natl Compr Cancer Netw"},{"key":"938_CR9","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546\u201358. https:\/\/doi.org\/10.1126\/science.1235122.","journal-title":"Science"},{"key":"938_CR10","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1158\/1055-9965.EPI-13-0568","volume":"23","author":"JB Hjelmborg","year":"2014","unstructured":"Hjelmborg JB, Scheike T, Holst K, Skytthe A, Penney KL, Graff RE, et al. The heritability of prostate cancer in the Nordic twin study of cancer. Cancer Epidemiol Biomark Prev. 2014;23:2303\u201310.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"938_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5114\/wo.2014.47136","volume":"1A","author":"K Tomczak","year":"2015","unstructured":"Tomczak K, Czerwi\u0144ska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Wspolczesna Onkologia. 2015;1A:68\u201377. https:\/\/doi.org\/10.5114\/wo.2014.47136.","journal-title":"Wspolczesna Onkologia"},{"key":"938_CR12","unstructured":"Dansk Prostata Cancer Gruppe, Dansk Urologisk Selskab, DaProCa. Guideline Landsd\u00e6kkende klinisk retningslinje til udredning og opf\u00f8lgning ved heredit\u00e6r disposition til prostatacancer. 2023."},{"key":"938_CR13","unstructured":"Danske Multidisciplin\u00e6re Cancer Grupper. Arvelig mammacancer- Henvisningskriterier til genetisk r\u00e5dgivning, indikation for tilbud om surveillance og profylaktisk kirurgi. 2023. https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/brystcancer\/arvelig-mammacancer--henvisningskriterier-til-genetisk-radgivning-indikation-for-tilbud-om-surveillance-og-profylaktisk-kirurgi\/ (accessed Mar 14, 2024)."},{"key":"938_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-01004-8","volume":"14","author":"CG Preston","year":"2022","unstructured":"Preston CG, Wright MW, Madhavrao R, Harrison SM, Goldstein JL, Luo X, et al. ClinGen Variant Curation Interface: a variant classification platform for the application of evidence criteria from ACMG\/AMP guidelines. Genome Med. 2022;14:6. https:\/\/doi.org\/10.1186\/s13073-021-01004-8.","journal-title":"Genome Med"},{"key":"938_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.clgc.2017.05.024","volume":"15","author":"HH Cheng","year":"2017","unstructured":"Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS. Prostate cancer screening in a new era of genetics. Clin Genitourin Cancer. 2017;15:625\u20138. https:\/\/doi.org\/10.1016\/j.clgc.2017.05.024.","journal-title":"Clin Genitourin Cancer"},{"key":"938_CR16","unstructured":"Lar\u00f8nningen S, Ferlay J, Bray F, Engholm G, Ervik M, Gulbrandsen J et al. NORDCAN: Cancer incidence, mortality, prevalence and survival in the Nordic countries, Version 9.1 (27.09.2021). Association of the Nordic Cancer Registries. Cancer Registry of Norway. 2021. https:\/\/nordcan.iarc.fr\/ (accessed Jan 20, 2022)."},{"key":"938_CR17","unstructured":"Statistics Denmark. https:\/\/www.statbank.dk\/statbank5a\/default.asp?w=1920 (accessed Feb 13, 2024)."},{"key":"938_CR18","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: Improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062\u2013D1067. https:\/\/doi.org\/10.1093\/nar\/gkx1153.","journal-title":"Nucleic Acids Res"},{"key":"938_CR19","doi-asserted-by":"publisher","unstructured":"D\u2019Amico AV, Whittington R, Bruce Malkowicz S, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc. 1998. https:\/\/doi.org\/10.1001\/jama.280.11.969.","DOI":"10.1001\/jama.280.11.969"},{"key":"938_CR20","unstructured":"DaProCa. G\u00e6ldende kliniske retningslinjer. Dansk Urologisk Cancer Gruppe (DUCG). 2023. https:\/\/ducg.dk\/daproca-prostatacancer\/kliniske-retningslinjer\/ (accessed Feb 7, 2024)."},{"key":"938_CR21","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","volume":"76","author":"EC Page","year":"2019","unstructured":"Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, et al. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol. 2019;76:831\u201342.","journal-title":"Eur Urol"},{"key":"938_CR22","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","volume":"68","author":"E Castro","year":"2015","unstructured":"Castro E, Goh C, Leongamornlert D, Saunders E, Tymrakiewicz M, Dadaev T, et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol. 2015;68:186\u201393. https:\/\/doi.org\/10.1016\/j.eururo.2014.10.022.","journal-title":"Eur Urol"},{"key":"938_CR23","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","volume":"31","author":"E Castro","year":"2013","unstructured":"Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31:1748\u201357. https:\/\/doi.org\/10.1200\/JCO.2012.43.1882.","journal-title":"J Clin Oncol"},{"key":"938_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s10916-023-01991-8","volume":"47","author":"HV Stroomberg","year":"2023","unstructured":"Stroomberg HV, Larsen SB, Lanth\u00e9n GS, Nielsen TK, Helgstrand JT, Brasso K, et al. Danish Prostate Registry (DanProst)\u2014an Updated Version of the Danish prostate cancer registry, methodology, and early results. J Med Syst. 2023;47:98. https:\/\/doi.org\/10.1007\/s10916-023-01991-8.","journal-title":"J Med Syst"},{"key":"938_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.11.013","volume":"85","author":"O Bratt","year":"2024","unstructured":"Bratt O, Godtman RA, Jiborn T, Wallstr\u00f6m J, Akre O, Carlsson S, et al. Population-based organised prostate cancer testing: results from the first invitation of 50-year-old Men. Eur Urol 2023. 2024;85:207\u201314. https:\/\/doi.org\/10.1016\/j.eururo.2023.11.013.","journal-title":"Eur Urol 2023"},{"key":"938_CR26","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1056\/nejmoa2209454","volume":"387","author":"J Hugosson","year":"2022","unstructured":"Hugosson J, M\u00e5nsson M, Wallstr\u00f6m J, Axcrona U, Carlsson SV, Egevad L, et al. Prostate cancer screening with PSA and MRI followed by targeted biopsy only. N Engl J Med. 2022;387:2126\u201337. https:\/\/doi.org\/10.1056\/nejmoa2209454.","journal-title":"N Engl J Med"},{"key":"938_CR27","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/ijc.33940","volume":"150","author":"C Arsov","year":"2022","unstructured":"Arsov C, Albers P, Herkommer K, Gschwend J, Imkamp F, Peters I, et al. A randomized trial of risk-adapted screening for prostate cancer in young men\u2014results of the first screening round of the PROBASE trial. Int J Cancer. 2022;150:1861\u20139. https:\/\/doi.org\/10.1002\/ijc.33940.","journal-title":"Int J Cancer"},{"key":"938_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/bju.15997","volume":"132","author":"HV Stroomberg","year":"2023","unstructured":"Stroomberg HV, Andersen MCM, Helgstrand JT, Larsen SB, Vickers AJ, Brasso K, et al. Standardized prostate cancer incidence and mortality rates following initial non-malignant biopsy result. BJU Int. 2023;132:181\u20137. https:\/\/doi.org\/10.1111\/bju.15997.","journal-title":"BJU Int"},{"key":"938_CR29","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/jnci\/djm005","volume":"99","author":"L Tryggvad\u00f3ttir","year":"2007","unstructured":"Tryggvad\u00f3ttir L, Vidarsd\u00f3ttir L, Thorgeirsson T, Jonasson JG, \u00d3lafsd\u00f3ttir EJ, \u00d3lafsd\u00f3ttir GH, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99:929\u201335. https:\/\/doi.org\/10.1093\/jnci\/djm005.","journal-title":"J Natl Cancer Inst"},{"key":"938_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","volume":"77","author":"T Nyberg","year":"2020","unstructured":"Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, et al. Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Eur Urol. 2020;77:24\u201335. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.025.","journal-title":"Eur Urol"},{"key":"938_CR31","unstructured":"Mottet N, Cornford P, van den Bergh RCN, Briers E, Eberli D, De Meerlerr G et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2023. (2023)."},{"key":"938_CR32","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.euf.2019.05.009","volume":"6","author":"D Halstuch","year":"2020","unstructured":"Halstuch D, Ber Y, Margel D. Screening, active surveillance, and treatment of localized prostate cancer among carriers of germline BRCA mutations. Eur Urol Focus. 2020;6:212\u20134. https:\/\/doi.org\/10.1016\/j.euf.2019.05.009.","journal-title":"Eur Urol Focus"},{"key":"938_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41585-022-00680-4","volume":"20","author":"P Rajwa","year":"2023","unstructured":"Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman MS, et al. Prostate cancer risk, screening and management in patients with germline BRCA1\/2 mutations. Nat Rev Urol. 2023;20:205\u201316. https:\/\/doi.org\/10.1038\/s41585-022-00680-4.","journal-title":"Nat Rev Urol"},{"key":"938_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.eururo.2021.03.031","volume":"80","author":"JE Berchuck","year":"2021","unstructured":"Berchuck JE, Zhang Z, Silver R, Kwak L, Xie W, Lee GSM, et al. Impact of pathogenic germline DNA damage repair alterations on response to intense neoadjuvant androgen deprivation therapy in high-risk localized prostate cancer. Eur Urol. 2021;80:295\u2013303. https:\/\/doi.org\/10.1016\/j.eururo.2021.03.031.","journal-title":"Eur Urol"},{"key":"938_CR35","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/JU.0000000000001027","volume":"204","author":"D Halstuch","year":"2020","unstructured":"Halstuch D, Ber Y, Kedar D, Golan S, Baniel J, Margel D. Short-term outcomes of active surveillance for low risk prostate cancer among men with germline DNA repair gene mutations. J Urol. 2020;204:707\u201313. https:\/\/doi.org\/10.1097\/JU.0000000000001027.","journal-title":"J Urol"},{"key":"938_CR36","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/nejmoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443\u201353. https:\/\/doi.org\/10.1056\/nejmoa1603144.","journal-title":"N Engl J Med"},{"key":"938_CR37","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.annonc.2020.06.025","volume":"31","author":"N Segal","year":"2020","unstructured":"Segal N, Ber Y, Benjaminov O, Tamir S, Yakimov M, Kedar I, et al. Imaging-based prostate cancer screening among BRCA mutation carriers\u2014results from the first round of screening. Ann Oncol. 2020;31:1545\u201352. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.025.","journal-title":"Ann Oncol"},{"key":"938_CR38","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S0022-5347(05)67809-3","volume":"163","author":"FH Schr\u00f6der","year":"2000","unstructured":"Schr\u00f6der FH, Van Der Cruijsen-Koeter I, De Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol. 2000;163:806\u201312. https:\/\/doi.org\/10.1016\/S0022-5347(05)67809-3.","journal-title":"J Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00938-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00938-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00938-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:04:30Z","timestamp":1764083070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00938-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-00938-z","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Institutional Review Board (R-23066301; P-2023-15060). Oral informed consent was provided by the participants at the time of referral. Data reporting followed the STROBE reporting guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and approvals"}}]}}